Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Diagnostics » Companion Diagnostics » Burning Rock Bio, CStone Pharmaceuticals to Codevelop CDx for Pralsetinib in China

Burning Rock Bio, CStone Pharmaceuticals to Codevelop CDx for Pralsetinib in China

Jun 29, 2020
|
staff reporter

NEW YORK – Chinese molecular diagnostics firm Burning Rock Biotech announced Sunday a strategic collaboration with CStone Pharmaceuticals to co-develop and commercialize companion diagnostics for Blueprint Medicines' pralsetinib in China.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Hoax Account Uncovered

The founder of MeTooSTEM, BethAnn McLaughlin, created a Twitter account purported to be that of an LGBTQ Native American professor at Arizona State University, the New York Times writes.

More Promising Results

Novavax reports its candidate SARS-CoV-2 vaccine leads to immune responses, according to the Sydney Morning Herald.

All Ready for Shark Week?

Gene length is associated with lifespan in a comparative genomics study appearing in the Proceedings of the National Academy of Sciences that draws on the whale shark genome.

Nucleic Acids Research Studies on Rat Transcriptome, Marine Metagenomic Tool, More

In Nucleic Acids Research this week: effort to annotate the rat transcriptome, web-based resource to characterize marine microbes, and more.

Aug
18
Featured Webinar

COVID-19 Wastewater-Based Epidemiology: Methods and Insights for SARS-CoV-2 Community Surveillance

Sponsored by
Bio-Rad

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Sep
17
Featured Webinar

Clinical Diagnosis of Developmental Disorders with Chromosomal Microarrays

Sponsored by
Thermo Fisher Scientific

The prevalence of developmental disability among US children aged 3 to 17 years increased between 2009 and 2017, with as many as 1 in 6 children in the US reported to have a developmental disability diagnosis.

What's Popular?

In Companion Diagnostics

  1. Guardant Health Enters CDx Collaboration With Radius Health for Elacestrant in HER2- Breast Cancer

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.